Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.

• Material Type: 博士論文
• Title: Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.
• Author/Editor: Ogawa, Hiroyuki; Kaji, Kosuke; Nishimura, Norihisa; Takagi, Hirotetsu; Ishida, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
• Author Heading: Ogawa, Hiroyuki; Kaji, Kosuke; Nishimura, Norihisa; Takagi, Hirotetsu; Ishida, Koji; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Yoshiji, Hitoshi
• Publication, Distribution, etc.: John Wiley & Sons
• Publication Date: 2021-04
• Publication Date (W3CDTF): 2021-04
• Alternative Title: レンバチニブは実験的肝線維症において肝星細胞の活性化と類洞毛細血管化を阻害することにより肝線維化を抑制する。
• Periodical title: Journal of cellular and molecular medicine Vol. No. p.- (2021 Apr)
• No. or year of volume/issue: 25 8
• Volume: 25
• Issue: 8
• Pages: 4001-4013
• ISSN (Periodical Title): ISSN : 1582-1838
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2022-03-15
• Dissertation Number: 甲第812号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: angiogenesis; hepatic stellate cell; lenvatinib; liver fibrosis; PDGF; VEGF
• Target Audience: 一般
• Note (General): type:Thesis; Molecular targeted agents are pharmacologically used to treat liver fibrosis and have gained increased attention. The present study examined the preventive effect of lenvatinib on experimental liver fibrosis and sinusoidal capillarization as well as the in vitro phenotypes of hepatic stellate cells. LX-2, a human stellate cell line, was used for in vitro studies. In vivo liver fibrosis was induced in F344 rats using carbon tetrachloride by intraperitoneal injection for 8 weeks, and oral administration of lenvatinib was started two weeks after initial injection of carbon tetrachloride. Lenvatinib restrained proliferation and promoted apoptosis of LX-2 with suppressed phosphorylation of extracellular signal-regulated kinase 1/2 and AKT. It also down-regulated COL1A1, ACTA2 and TGFB1 expressions by inhibiting the transforming growth factor-β1/Smad2/3 pathway. Treatment with lenvatinib also suppressed platelet-derived growth factor-BB-stimulated proliferation, chemotaxis and vascular endothelial growth factor-A production, as well as basic fibroblast growth factor-induced LX-2 proliferation. In vivo study showed that lenvatinib attenuated liver fibrosis development with reduction in activated hepatic stellate cells and mRNA expression of profibrogenic markers. Intrahepatic neovascularization was ameliorated with reduced hepatic expressions of Vegf1, Vegf2 and Vegfa in lenvatinib-treated rats. Collectively, these results suggest the potential use of lenvatinib as a novel therapeutic strategy for liver fibrosis.; 博士（医学）・甲第812号・令和4年3月15日; © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.; identifier:Journal of cellular and molecular medicine Vol.25 No.8 p.4001-4013 (2021 Apr); identifier:15821838; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3995; identifier:Journal of cellular and molecular medicine Vol. No. p.- (2021 Apr), 25(8): 4001-4013
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.1111/jcmm.16363
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3995/1/01%e7%94%b2812%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3995/2/02%e7%94%b2812%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3995/3/03%e7%94%b2812%e6%9c%ac%e6%96%87.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3995/4/04%e7%94%b2812Suppl..pdf fulltext